Sarepta Therapeutics
SRPTNASDAQRNA exon-skipping and AAV gene therapy for neuromuscular disorders
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
ENVISION: Delandistrogene moxeparvovec in Duchenne muscular dystrophy — primary completion
2027-05-31
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Elevidys | Duchenne muscular dystrophy | Approved | Not disclosed | ▼ |
| Casimersen | DMD exon 45 skipping | Approved | Not disclosed | ▼ |
| SRP-5051 | Duchenne muscular dystrophy | Phase 2 | Not disclosed | ▼ |
Analysis
Comparable companies
Sponsored
Get premium SRPT analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you